ArticleCancer diagnosis & prognosis
Prognostic Impact of Sarcopenia on Clinical Outcomes in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sarcopenia and Survival in Patients With Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis of Prognostic Association.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Impact of C3 Vertebra-Based Sarcopenia and Clinical Factors on Postoperative Complications in Oral Cancer Patients.Cancers · 2026Article
- Article
- The Role of Salvage Chemotherapy on Survival Outcomes Following Immune Checkpoint Inhibitor Therapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Poor nutritional status is one of the key contributing factors to sarcopenia, which negatively influences postoperative complications and clinical outcomes in patients with head and neck squamous cell carcinoma (HNSCC). This study aimed to investigate the potential association between sarcopenia and clinical outcomes in patients with recurrent and/or metastatic HNSCC treated with immune checkpoint inhibitors (ICIs). Patients and Methods: A retrospective review was conducted on the medical records of 119 patients with recurrent and/or metastatic HNSCC who received ICI therapy. Results: The objective response rates (ORRs) were 30.7% in the non-sarcopenia group and 15.8% in the sarcopenia group, showing a statistically significant difference between the two groups ( Conclusion: These findings underscore the detrimental impact of sarcopenia on the efficacy of immune checkpoint inhibitor therapy in patients with recurrent and/or metastatic HNSCC. Careful consideration of sarcopenia is warranted in the clinical management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.